Researchers at the University of Michigan have had initial success in mice using nanodiscs to deliver a customized therapeutic vaccine for the treatment of colon and melanoma cancer tumors.
“We are basically educating the immune system with these nanodiscs so that immune cells can attack cancer cells in a personalized manner,” said James Moon, the John Gideon Searle assistant professor of pharmaceutical sciences and biomedical engineering.
Personalized immunotherapy is a fast-growing field of research in the fight against cancer.
The therapeutic cancer vaccine employs nanodiscs loaded with tumor neoantigens, which are unique mutations found in tumor cells. By generating T-cells that recognize these specific neoantigens, the technology targets cancer mutations and fights to eliminate cancer cells and prevent tumor growth.
Unlike preventive vaccinations, therapeutic cancer vaccines of this type are meant to kill established cancer cells.
“The idea is that these vaccine nanodiscs will trigger the immune system to fight the existing cancer cells in a personalized manner,” Moon said.
The nanodisc technology was tested in mice with established melanoma and colon cancer tumors. After the vaccination, twenty-seven percent of T-cells in the blood of the mice in the study targeted the tumors.
When combined with immune checkpoint inhibitors, an existing technology that amplifies T-cell tumor-fighting responses, the nanodisc technology killed tumors within 10 days of treatment in the majority of the mice. After waiting 70 days, researchers then injected the same mice with the same tumor cells, and the tumors were rejected by the immune system and did not grow.
“This suggests the immune system ‘remembered’ the cancer cells for long-term immunity,” said Rui Kuai, U-M doctoral student in pharmaceutical sciences and lead author of the study.
“The holy grail in cancer immunotherapy is to eradicate tumors and prevent future recurrence without systemic toxicity, and our studies have produced very promising results in mice,” Moon said.
The technology is made of extremely small, synthetic high density lipoproteins measuring roughly 10 nanometers. By comparison, a human hair is 80,000 to 100,000 nanometers wide.
“It’s a powerful vaccine technology that efficiently delivers vaccine components to the right cells in the right tissues. Better delivery translates to better T-cell responses and better efficacy,” said study co-senior author Anna Schwendeman, U-M assistant professor of pharmacy.
The next step is to test the nanodisc technology in a larger group of larger animals, Moon said.
Receive an email update when we add a new PERSONALIZED IMMUNOTHERAPY article.
The Latest on: Personalized immunotherapy
via Google News
The Latest on: Personalized immunotherapy
- John Theurer Cancer Center launches clinical trial of personalized cancer vaccineon February 28, 2020 at 10:57 am
John Theurer Cancer Center at Hackensack University Medical Center said Friday that it is the only site in New Jersey, and one of just 17 in the country, participating in a multicenter international ...
- Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?on February 28, 2020 at 10:44 am
The continuous development of such biomarkers would offer new perspectives and more personalized treatments by targeting oncological options, including ICIs, which modify the tumour-immune ...
- John Theurer Cancer Center Launches Clinical Trial of Personalized Cancer Vaccine Using New Gene-Based Technology for High-Risk Melanomaon February 28, 2020 at 8:45 am
/PRNewswire/ -- John Theurer Cancer Center at Hackensack University Medical Center is the only site in New Jersey and one of just 17 in the ...
- How Close Are We to a Cure for Melanoma?on February 27, 2020 at 1:16 pm
Immunotherapy helps your natural immune system to attack cancer cells ... According to an article in Gland Surgery, early research findings suggest that personalized anti-tumor vaccines may be a safe ...
- The Quest for a Personalized Genomic Vaccine in Myelomaon February 27, 2020 at 6:53 am
A response to immunotherapy was confirmed in 3 patients with relapsed multiple myeloma. Somatic mutations in multiple myeloma can be immunogenic, and neoantigen-targeted immunotherapy can generate an ...
- Cancer Immunotherapy Market is Registering a CAGR of 7.5% and Expected To Garner USD 86,678.7 Million By The End of 2027on February 27, 2020 at 5:25 am
The global Cancer Immunotherapy market reached USD 42,584.18 Million in 2017 by registering a CAGR of 7.5% across the globe. Moreover, the market is expected to garner USD 86,678.7 Million by the end ...
- CoImmune, Inc. Announces FDA Approval of its IND Application to Conduct a Phase 2b Clinical Trial with CMN-001 in Advanced RCC Patientson February 19, 2020 at 5:00 am
DURHAM, N.C., Feb. 19, 2020 (GLOBE NEWSWIRE) -- CoImmune, Inc. announced today that the FDA approved its investigational new drug application (IND) and that it is cleared to move forward with a Phase ...
- Predicting immunotherapy successon February 18, 2020 at 10:15 am
This is as true of the newer immunotherapy treatments as it is of older types of chemotherapy ... on the understanding that learning to predict which treatments are most likely to work is the first ...
- Personalized Immunotherapy Could be the Future for Advanced Breast Cancer Treatmenton February 10, 2020 at 11:17 pm
Before it's here, it's on the Bloomberg Terminal.
via Bing News